Project Grant R43AI120246

The Project Grant award R01AI189503, totaling $747,763, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of this project is to develop small molecule inhibitors of the LPXH enzyme, which is essential for the lipid A biosynthetic pathway, as novel antibiotics to treat multidrug-resistant Enterobacterales infections. The award supports the design, synthesis, and optimization of...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $802,798 to The Research Foundation For The State University Of New York (RF SUNY) to develop novel biamyxin antibiotics targeting multidrug-resistant Gram-negative bacterial infections. The goal is to identify a qualified lead development candidate by Year 4 and pursue an Investigational New Drug (IND) candidate...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $749,417 to support research focused on developing novel antibiotics to address the growing problem of multi-drug resistant pathogens. The research aims to synthesize and biologically evaluate a modular platform of antibiotics that target the localization of lipoproteins (Lol) pathway in gram-negative bacteria,...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $241,500 to New York University (NYU) to develop a high-throughput screening approach to discover protein-based efflux pump inhibitors (EPIs). The goal is to identify compounds that can block antibiotic resistance mechanisms in pathogenic bacteria without the need for sample optimization, thereby expediting the...

This $569,210 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to characterize key enzymes responsible for lipid A modification, a mechanism that confers antibiotic resistance in certain gram-negative bacteria. The project aims to develop inhibitors targeting these enzymes, which could potentiate the efficacy of the antibiotic colistin against deadly...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $254,478.00 to The University of Texas Southwestern Medical Center to identify mechanisms of resistance to pathogen-specific antibacterial antisense compounds and develop strategies to circumvent them. The project aims to determine the mechanisms of resistance for lead peptide-phosphorodiamidate...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is supporting Curza Inc.'s development of a new class of broad-spectrum oral antibiotics focused on treating multidrug-resistant (MDR) Gram-negative bacterial infections. The $1,000,000 award, with a performance period from Jul 9, 2024 to Jun 30, 2027, will advance Curza's CZ-02 antibiotic program through several key research...

This $195,625 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to structurally and functionally characterize phosphoethanolamine (PEtN) transferases responsible for conferring resistance to cationic antimicrobial peptides (CAMPs) and the antibiotic colistin in certain Gram-negative bacterial pathogens. The goal is to develop inhibitors of the PEtN transferase...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $741,917 in funding to the West Virginia University Research Corporation to develop therapeutic antibodies for the treatment of multidrug-resistant Pseudomonas aeruginosa infections, with a focus on sepsis. The key objectives of this 5-year project are to: 1) characterize the mechanism of action of a lead antibody...

This Project Grant award of $275,000 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a platform for detecting genetic antibiotic resistance motifs that can predict current and future susceptibility to therapeutics. The award recipient, Informuta, Inc., will establish the feasibility of leveraging mutational signatures found in bacterial DNA to predict antibiotic resistance status. The project aims to...